BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33314168)

  • 21. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
    Xu W; Tang Y; Song H; Shi S; Yang S
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
    J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding hemoglobin contribution to high-dose methotrexate disposition-population pharmacokinetics in pediatric patients with hematological malignancies.
    Škorić B; Jovanović M; Kuzmanović M; Miljković B; Vučićević K
    Eur J Clin Pharmacol; 2024 May; 80(5):697-705. PubMed ID: 38347227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study.
    Schmidt D; Kristensen K; Schroeder H; Wehner PS; Rosthøj S; Heldrup J; Damsgaard L; Schmiegelow K; Mikkelsen TS
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27637. PubMed ID: 30835935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function.
    Barreto JN; Reid JM; Thompson CA; Mara KC; Rule AD; Kashani KB; Leung N; Larson TR; McGovern RM; Witzig TE; Barreto EF
    Clin Transl Sci; 2022 Jan; 15(1):105-117. PubMed ID: 34378331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
    Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
    Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
    Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.
    Gallais F; Oberic L; Faguer S; Tavitian S; Lafont T; Marsili S; Brice A; Chatelut E; Puisset F
    Ther Drug Monit; 2021 Jun; 43(3):408-415. PubMed ID: 32925658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate concentrations and associated variability factors in high dose therapy of children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Škorić B; Kuzmanović M; Jovanović M; Miljković B; Micić D; Jović M; Jovanović A; Vučićević K
    Pediatr Hematol Oncol; 2023; 40(5):446-457. PubMed ID: 37195735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients.
    Kawakatsu S; Nikanjam M; Lin M; Le S; Saunders I; Kuo DJ; Capparelli EV
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1339-1348. PubMed ID: 31586225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.